Through the partnership, Brainlab will aid Medineering as it works towards becoming a surgical robotic manufacturer, the companies said. Funds from the round support the commercialization of Medineering’s 1st robot, designed for endo and transnasal surgery.
“We started the development of our modular platform in October 2014 consisting of an intelligent arm and application specific robotic hands, which can be exchanged depending on the surgical needs. We got a great feedback for the first prototypes of our robotic hand for endo- and transnasal surgery. This motivated us to open our platform also for third-party robotic hands and instruments, depending on the dedicated surgical tasks. The success story of Brainlab has motivated and inspired us from the early stage of Medineering,” Medineering CEO & co-founder Stephan Nowatschin said in a press release.
“We were impressed by the potential of the technology, the ambitious founders and the team of Medineering. The promising approach of Medineering addresses reasonably the surgical needs of robotic assistance in the OR,” Brainlab exec VP Rainer Birkenbach said in a prepared statement.
“We are very pleased about Brainlab’s trust and feel even more encouraged in our vision of establishing new ways in minimally invasive surgery. Soon we will present the first robot for endo- and transnasal approaches supporting surgeons facing anatomically complex working spaces with robotic assistance,” Medineering CTO & co-founder Maximilian Krinninger said in a prepared release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.